Redeye comments on the recent phase Ia data from the Oxford-led BIO-002 study evaluating the RH5.1 malaria antigen produced using the ExpreS2 platform. The results showed favourable safety, functional antibody responses, and comparable immunogenicity across dosing regimens, supporting efficient antigen use and scalability. The data provide independent clinical validation of the platform and indirectly de-risk manufacturability for both infectious disease programs and internal assets such as ES2B-C001.
LÄS MER
